Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib and Durvalumab after TRT in ES-SCLC
NCT04314297Phase 2Unknown
- Start
- Apr 2020
- Primary completion
- Feb 2021
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and durvalumab in small cell lung cancer (SCLC). Primary endpoint: Progression-Free Survival at 1 year. Status: unknown.
02
Drugs
anlotinibdurvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04314297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04314297.